Protara Q2 net loss $15M; cash $145.6M into mid-2027; key trial readouts set

Protara Therapeutics, Inc.

2025-Q2 EPS reported -$0.65 vs consensus -$0.41 ▼ miss (-57.3%)

Q2 2025 net loss $15.0M ($0.35/shr) vs $9.5M ($0.45/shr) in Q2 2024; R&D spend up to $10.8M.
Cash, equivalents and investments $145.6M at June 30, expected to fund operations into mid-2027.
Interim data from ~25 BCG-unresponsive NMIBC patients (ADVANCED-2 trial) expected at 1Q 2026 medical conference.
First patient in THRIVE-3 Phase 3 registrational trial of IV Choline Chloride on track for 3Q 2025.
Appointed William Conkling as Chief Commercial Officer in June 2025; added to Russell 3000 Index.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.